Seoul, Korea — 19–22 March 2026 — Genèse Labs took part in the 41st Korea International Medical & Hospital Equipment Show (KIMES 2026) at COEX, unveiling its first launches of 2026 — the NAD⁺ skin booster NADX³ and the botulinum toxin AxeniQ™ — for the first time in Korea. Over four days, the booth was busy from opening to close with practitioners and distribution partners.

• Participation in Korea’s largest medical exhibition, with around 1,350 exhibitors and more than 75,000 visitors

• First Korean presentation of the 2026 launches NADX³ and AxeniQ™

• In skin-booster-driven Korea, enquiries centred on NADX³ and Exoluma™ Exo-PDRN

• A successful show, with visitors queuing at the booth throughout

Held since 1980 and having grown alongside Korea’s medical industry, KIMES is the country’s largest specialised exhibition for medical devices and hospital equipment. Genèse Labs chose KIMES as the first stage for its 2026 launches — a clear signal of Korea’s importance as a core strategic market.

NADX³, a longevity skin booster combining NAD⁺, NMN and NR, and AxeniQ™, a botulinum toxin in 100-unit and 200-unit presentations, were unveiled here for the first time in Korea. Partners paid close attention to both, as they mark Genèse Labs’ move into two new categories: longevity and neuromodulators.

Korea has the world’s most developed skin-booster culture, with a strong focus on skin texture and skin health from within. Reflecting this, enquiries centred on NADX³, with its new perspective on cellular energy, alongside the salmon DNA-derived PDRN of Exoluma™ Exo-PDRN and the recombinant collagen of Proluma™ RH Collagen. KFDA-approved Réluma also drew steady interest from Korean practitioners.

From opening day to close, dermatologists, plastic surgeons and domestic and international distributors kept the booth full, with visitors queuing for product consultations throughout the show. The enthusiastic response at KIMES carried directly into the global launch at AMWC Monaco a week later.

Genèse Labs is a Paris-founded aesthetic company dedicated to science-based, regulatory-led product development across body contouring, collagen biostimulation, fillers, neuromodulators, and longevity and regenerative skincare. Since its foundation in 2019, the company has built its portfolio — including the RG Body Filler line, Proluma™ (PDLLA, PLLA and RH Collagen), Réluma, SofistiCa, AxeniQ™, NADX³, Aqua Feel, MESO PEPTA™, Citrus Bottle™, Exoluma™ (Human, Plant and Exo-PDRN) and Exo-Mask — on three principles: scientifically verifiable formulations, regulatory compliance in every market entered, and continuous engagement with the international clinical and academic community. Genèse Labs partners with dermatologists, aesthetic physicians and distributors worldwide to advance the standard of modern aesthetic medicine. For more information: www.geneselabs.net.